Gastroenterology
From the Journals
CDC recommends screening all adults for hepatitis B
“Risk-based testing alone has not identified most persons living with chronic HBV infection and is considered inefficient for providers to...
From the Journals
Patient-based mouse MVID model hints at mechanism
A method using gene editing at the two-cell stage recreated in mice the phenotype of a patient with two separate mutations.
Feature
Are you misdiagnosing IBS? Watch out for this mimic
A 39-year-old’s flare-ups were caused by some foods that aren’t typical IBS triggers.
Conference Coverage
Crohn’s disease remission rates ‘remarkably higher’ with vedolizumab
Findings may influence physicians to select vedolizumab over anti-TNF therapy as first-line biologic for CD.
Pearl of the Month
What do high BUN/Cr ratios mean?
What is the most likely source of this patient’s bleeding?
From the Journals
EoE: One-food elimination works as well as six-food elimination
“The takeaway message is that one-food (milk) elimination is an effective treatment and a reasonable first-line treatment for EoE.”
Conference Coverage
Ileocecal resection possible first-line option in early Crohn’s disease
Patients with early ileocecal Crohn’s disease who undergo ileocecal surgery remain off drug treatment 5 years later.
Conference Coverage
Pediatric IBD patients wrestle with lingering gut pain
Chronic pain in children and adolescents with IBD is not linked to disease activity, nonetheless it impacts emotional wellbeing which suggests...
From the Journals
Posttransplant NASH patients fare worse with older donor livers
“Given the possibility of infectious graft complications, post–liver transplant follow-ups may need to be more comprehensive and frequent in these...
Conference Coverage
DNA panels could predict endoscopic response to biologics in Crohn’s disease
Adding biomarkers to improve biologic medication selection is “urgently needed ... however, such biomarkers are not available for practice today...
Conference Coverage
IBD: More patients on vedolizumab vs. anti-TNFs at 2 years
Vedolizumab showed a higher overall 1- and 2-year persistence of use, compared with two anti–tumor necrosis factor inhibitors in both Crohn’s...